The first choice treatment for late syphilis is penicillin. Other than doxycycline, which penetrates the CNS, there are few alternatives for the treatment of neurosyphilis. We report a case of successful treatment of symptomatic neurosyphilis with parenteral ceftriaxone.

A 61 year old heterosexual man who had served in the armed forces abroad was referred to the department of genitourinary medicine with a diagnosis of symptomatic neurosyphilis in September 1997.

Six months before this he had been admitted to hospital with a history of expressive dysphasia and a left sided hemiparesis. His behaviour had been noted to be “out of character” for a week before the admission. A computed tomograph (CT) scan revealed patchy ischaemic change, especially of the left frontal lobe. A carotid duplex scan and ECG were normal but an echocardiogram revealed a trivial degree of aortic regurgitation. His neurological abnormalities resolved over several days and he was discharged.

In June 1997 he was reviewed in the neurology outpatient clinic with a history of transient dysphasia and impaired use of his right hand. He had developed marked short term memory loss and was unable to perform simple tasks. On examination he was generally tremulous and dysarthric but with normal tendon reflexes, tone, power, pain, and vibration sensation and proprioception. A magnetic resonance imaging (MRI) scan revealed generalised prominence of CSF spaces disproportionate to the patient’s age and small vessel ischaemic damage within both frontal lobes.

He was readmitted to hospital in August 1997 with a history of frequent falls. He was confused and had delusions of persecution. Investigations revealed positive syphilis serology in blood and CSF (see table 1) and he was referred to the department of genitourinary medicine.

A diagnosis of untreated symptomatic neurosyphilis was made with both cerebrovascular components and parenchymatous features of general paresis. He had a history of anaphylaxis with penicillin and there were concerns about non-compliance with doxycycline. We decided to use ceftriaxone because of its good CNS penetration. There is a 10% risk of cross sensitivity between penicillin and cephalosporins; therefore, he was admitted to hospital and given a test dose of 50 mg of ceftriaxone intravenously with full resuscitation facilities available. He was commenced on prednisolone 10 mg three times daily for 24 hours before and 48 hours after starting treatment because of the risk of a Jarisch-Herxheimer reaction causing neurological deterioration or acute coronary ostitis. He received 1 g of ceftriaxone once daily for 14 days.

He was reviewed 7, 19, and 36 months after treatment with repeat syphilis serology of blood and CSF (see table 1). Clinically he made some improvement in terms of his memory, speech, and mobility.

**DISCUSSION**

The recommended treatment for neurosyphilis is penicillin. Doxycycline and amoxicillin have been evaluated as second line options but as they are given orally, there may be adherence issues. The UK national guidelines and the European guidelines for the management of syphilis do not recommend ceftriaxone for the treatment of late syphilis. However, the CDC Sexually Transmitted Diseases Treatment Guidelines 2002 suggest that it may be used as an alternative in penicillin allergic patients with neurosyphilis.

Ceftriaxone has been proved to have good CNS penetration. A dose of 1 g daily achieves levels well above the MIC for *Treponema pallidum* of 0.0006 µg/ml. It also differs from other cephalosporins by having an unusually long serum half life of approximately 7 hours.

However there have been reports that intramuscular ceftriaxone may not be adequate treatment for neurosyphilis. A retrospective study of HIV infected individuals treated with ceftriaxone for asymptomatic neurosyphilis or latent syphilis revealed a 23% failure rate. Another study suggested that intravenous ceftriaxone may be an alternative to penicillin for treatment of HIV infected patients with neurosyphilis complicating early syphilis infection. However, in this setting, disease may be confined to the meninges and parenteral meningitis and may be less susceptible to ceftriaxone.

**Table 1** Blood and CSF parameters before and after treatment with ceftriaxone

<table>
<thead>
<tr>
<th></th>
<th>Sept 97</th>
<th>April 98</th>
<th>April 99</th>
<th>Sept 00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPHA*</td>
<td>1 in 256</td>
<td>1 in 128</td>
<td>1 in 64</td>
<td>&gt;1 in 256</td>
</tr>
<tr>
<td>FTA abs</td>
<td>Pos</td>
<td>Pos</td>
<td>Pos</td>
<td>Pos</td>
</tr>
<tr>
<td>RPR</td>
<td>1 in 128</td>
<td>1 in 32</td>
<td>1 in 64</td>
<td>1 in 16</td>
</tr>
<tr>
<td>Albumin (g/l)</td>
<td>41</td>
<td>40</td>
<td>-</td>
<td>44</td>
</tr>
<tr>
<td>IgG (g/l)</td>
<td>14.1</td>
<td>9.9</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>Glucose (mmol/l)</td>
<td>4.3</td>
<td>3.7</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CSF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPHA*</td>
<td>1 in 64</td>
<td>1 in 32</td>
<td>1 in 32</td>
<td>&gt;1 in 256</td>
</tr>
<tr>
<td>FTA abs</td>
<td>Pos</td>
<td>Pos</td>
<td>Pos</td>
<td>Pos</td>
</tr>
<tr>
<td>RPR</td>
<td>1 in 4</td>
<td>neg</td>
<td>1 in 2</td>
<td>neg</td>
</tr>
<tr>
<td>Protein (g/l)</td>
<td>2.03</td>
<td>0.63</td>
<td>0.55</td>
<td>0.55</td>
</tr>
<tr>
<td>Albumin (mg/l)</td>
<td>-</td>
<td>418</td>
<td>-</td>
<td>262</td>
</tr>
<tr>
<td>IgG (mg/l)</td>
<td>97</td>
<td>&gt;120</td>
<td>81</td>
<td>81</td>
</tr>
<tr>
<td>White cells (x106)</td>
<td>32 &lt;10^6</td>
<td>&lt;1x10^6</td>
<td>&lt;1x10^6</td>
<td>&lt;1x10^6</td>
</tr>
<tr>
<td>Glucose (mmol/l)</td>
<td>2.5</td>
<td>2.8</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IgG index</td>
<td>(&lt;0.70)</td>
<td>0.94</td>
<td>0.91</td>
<td>0.91</td>
</tr>
<tr>
<td>Albumin quotient</td>
<td>10.45</td>
<td>5.95</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*TPHA = Treponema pallidum haemagglutination; FTA = fluorescent treponemal antibody; RPR = rapid plasmin reagin; TPHA = Treponema pallidum particle agglutination.*

*In January 2000 the laboratory began monitoring TPPA instead of TPHA.*
may be easier to cure than disease of longer duration that could involve meninges and brain parenchyma. The patient in our case had evidence of both cerebrovascular and parenchymal disease. He received 14 days of ceftriaxone (3 days intravenously and 11 days intramuscularly) and was followed up for 36 months with blood and CSF analysis. His blood RPR fell from 1 in 128 pre-treatment to 1 in 16 (a threefold reduction) 36 months after treatment. His CSF TPHA and FTA abs have remained detectable but the RPR was negative on the last occasion. The protein level in the CSF has consistently declined from 2.03 g/l to 0.55 g/l as have the CSF albumin and IgG levels. The IgG index remains elevated but the albumin quotient has normalised. Even after successful treatment these latter two parameters may remain abnormal.

There are few other reports of successful treatment of symptomatic neurosyphilis in HIV negative individuals with ceftriaxone. There is a single case of treatment of asymptomatic neurosyphilis and of treatment of meningomyelitis complicating secondary syphilis. Our case suggests that ceftriaxone may be a useful alternative in HIV negative patients with neurosyphilis, but because of the doubt about its efficacy in those who are co-infected, a larger study with CSF levels of ceftriaxone should be performed.

Authors’ affiliations
S Shann, J Wilson, Department of Genitourinary Medicine, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK

Correspondence to: Dr S Shann, Department of Genitourinary Medicine, Sunnybank Wing, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK; siobhan.mcmyle@leedsth.nhs.uk

Accepted for publication 27 February 2003

REFERENCES


2 Clinical Effectiveness Group. UK national guidelines on STIs and closely related conditions. Sex Transm Infect 1999;75(Supp 1).


Treatment of neurosyphilis with ceftriaxone

S Shann and J Wilson

*Sex Transm Infect* 2003 79: 415-416
doi: 10.1136/sti.79.5.415

Updated information and services can be found at:
[http://sti.bmj.com/content/79/5/415](http://sti.bmj.com/content/79/5/415)

These include:

**References**
This article cites 9 articles, 0 of which you can access for free at:
[http://sti.bmj.com/content/79/5/415#BIBL](http://sti.bmj.com/content/79/5/415#BIBL)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Syphilis (793)
- Infection (neurology) (47)
- Drugs: infectious diseases (3182)

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)